We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

PHVS Pharvaris NV

-0.04 (-0.19%)
After Hours
Last Updated: 15:06:05
Delayed by 15 minutes


Draw Mode:

Volume 34,153
Bid Price 20.84
Ask Price 24.00
News -
Day High 22.715


52 Week Range


Day Low 21.02
Share Name Share Symbol Market Stock Type
Pharvaris NV PHVS NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.04 -0.19% 21.25 15:06:05
Open Price Low Price High Price Close Price Previous Close
21.45 21.02 22.715 21.25 21.29
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
1,482 34,153 US$ 21.43 US$ 731,866 - 7.93 - 33.00
Last Trade Type Quantity Price Currency
15:04:24 formt 442 US$ 21.25 USD

Pharvaris NV Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
860.14M 40.82M - 0 -100.88M -2.47 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Pharvaris NV News

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No PHVS Message Board. Create One! See More Posts on PHVS Message Board See More Message Board Posts

Historical PHVS Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week21.3624.2017.5720.49133,993-0.11-0.51%
1 Month24.0725.1917.5721.2277,605-2.82-11.72%
3 Months30.0333.0017.5725.2892,813-8.78-29.24%
6 Months17.9733.0015.0025.08120,0323.2818.25%
1 Year9.0033.007.9322.9082,25312.25136.11%
3 Years26.0833.001.7712.13216,453-4.83-18.52%
5 Years25.0042.861.7712.89210,863-3.75-15.00%

Pharvaris NV Description

Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.

Your Recent History

Delayed Upgrade Clock